Leukemia and Lymphoma Society Equity and Access in Research Program
Deadline: September 12, 2024
3 pm
Amount: Funding Available
• Maximum project period is 5 years, and the maximum funding amount per year is
$500,000.
• Total budget, including indirect costs, should not exceed $2.5 million for a 5-year
project period.
• Indirect costs are limited to 11.1% of the total direct costs during the Research
Funding Term.
Purpose
This funding opportunity is part of LLS's Equity in Access Research Program, designed to generate evidence that will guide changes in healthcare policy and practice to ensure that all patients with and survivors of a blood cancer have the ability to access and utilize optimal treatment, care, and resources that can improve their quality of life andoutcomes, from diagnosis through survivorship.
With this RFP, LLS will support research that will guide changes in evidence-based practice and policy. LLS is particularly interested in proposals that address systemic, institutional, and/or clinician-related barriers that impede clinical trial participation.
Proposed research studies must:
- Measure change in the rate of accrual to therapeutic clinical trials over time among one or more underrepresented groups as the primary outcome;
applicants may choose to focus on a subset of trials or populations.
- Document that the institution(s) involved in the proposed research provide clinical care to a patient demographic where at least 30% of patients represent
underrepresented groups (e.g., patients from racial/ethnic minoritized groups, those residing in rural areas, patients with Medicaid, those over age 70, and/or
adolescents and young adults). The 30% threshold can be met through any one group or a combination of these groups.
- Include interventions and outcomes related to blood cancer therapeutic trials (leukemias, lymphomas, myeloma, myelodysplastic syndromes, and/or
myeloproliferative neoplasms). Interventions and outcomes may also include therapeutic trials for other cancers.
- Study interventions to increase accrual by addressing barriers at the structural/systematic, institutional, clinician/research team, and/or patient levels. Multi-level interventions are strongly preferred. Single-level interventions are less likely to be funded. Selected interventions cannot be only at the patient level.
- Test interventions that are based on promising preliminary intervention data; preliminary data can be internal or external and may be published or unpublished. This grant mechanism is not intended to fund pilot projects.
- Collect outcomes data that allow for a direct comparison, such as comparing accrual before and after an intervention is implemented or between two interventions alongside a control group.
- Be able to demonstrate the independent and aggregate effects of interventions conducted to increase accrual, as relevant.
- Involve key study stakeholders in shaping and executing the research (e.g., patients, community oncologists, patient navigators).